Journal of Radiotherapy

Review Article

Stereotactic Hypofractionated Irradiation for Metastatic, Inoperable, and Recurrent Malignancies: A Modern Necessity, rather than a Luxury

Table 3

Evidence for the use of SABR in treating hepatic metastases.
StudyRemarksConclusions
Rusthoven et al. [50]SABR (upto 20 Gy × 3 Fc) in patients with 1–3 hepatic metastases (none >6 cm). Median survival 20.5 months; 100% 2-year local control rates if maximum diameter <3 cm.
Katz et al. [54]Retrospective analysis of 69 patients with 174 hepatic metastases treated with SABR (dose range 30–55 Gy).No grade-3 toxicity. 76% LC at 10 months.
van der Pool et al. [55]Use of SABR (various doses) for 20 patients of hepatic metastases from colorectal malignancies who were not candidates for resection or radio frequency ablation.SABR is a viable option for colorectal liver metastases who are not candidates for resection or RFA. 2-year LC and OS at 74% and 83%, respectively. Observed rate of grade-3 toxicity at 10%.
Lanciano et al. [51]Use of SABR for patients with heavily pretreated liver tumours and metastases.Dose-dependent increase in local control, with 2-year LC being 75% versus 38% for BED of >100 Gy 10 versus <100 Gy 10 ().
Ambrosino et al. [52]Image guided SABR in 17 patients of unresectable liver metastases.74.1% patients had inhibition of growth or size reduction. 25.9% patients had complete response. Mild to moderate hepatic dysfunction in 33% patients.
Lee et al. [53]Phase-I trial () of SABR in hepatic metastases. Even at a dose of assuming 20% risk of radiation induced liver disease, there was no incidence of grade 3–5 liver toxicity. 1-year local control rate of 71%.
LC: local control; BED: biologically equivalent dose; RFA: radiofrequency ablation; OS: overall survival; Fc: fraction.